Elliot S Barnathan

8PUBLICATIONS
19CO-AUTHORS
PharmacogenomicsRespiratory diseasesEpidemiological modellingHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 02, 2024
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.

Zhong Yuan, Bennett Levitan, Hsiaowei Deng

|Nov 23, 2023
Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials.

Judith Hsia, Alex C Spyropoulos, Gregory Piazza

|May 08, 2023
Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.

Gregory Piazza, Alex C Spyropoulos, Judith Hsia

|Oct 27, 2022
Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study.

Alex C Spyropoulos, Gary E Raskob, Theodore E Spiro

|Oct 07, 2022
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.

Gary E Raskob, Walter Ageno, Gregory Albers

|Sep 01, 2022
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial.

Alex C Spyropoulos, Mark Goldin, Walter Ageno

Pageof 2

Frequent Collaborators

7 joint publications

Alex C Spyropoulos

3 joint publications

Gary E Raskob

2 joint publications

Walter Ageno

2 joint publications

Gregory W Albers